[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563041":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":55,"collaborators":20,"id":57,"slug":20,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":20,"enrollmentInfo":66,"targetDuration":20,"studyType":69,"phases":70,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University Hospital, Grenoble","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Arterial embolization of the hand with Lipiodol","EXPERIMENTAL","The radial artery will be embolized with Lipiodol emulsified 3:1 with iodinated contrast medium (Optiray 300 mg\u002Fml). The most painful hand according to VAS pain will be treated.",[13],"Drug: embolization therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","embolization therapy","Hand arterial embolization with Lipiodol in emulsion with iodinated contrast agent",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Xavier Romand, MD, PhD","CHU Grenoble Alpes, site Sud, France","PRINCIPAL_INVESTIGATOR",[27,32],{"name":23,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","0476767223","+33","xromand@chu-grenoble.fr",{"name":33,"role":28,"phone":20,"phoneExt":20,"email":34},"Emeric Gremen, MD","egremen@chu-grenoble.fr",[36],{"facility":37,"status":38,"city":39,"state":20,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"CHU Grenoble Alpes - Sud site","RECRUITING","Échirolles","38130","France",{"type":43,"coordinates":44},"Point",[45,46],5.71441,45.14603,{"lat":46,"lon":45},[49,51,54],{"name":50,"role":28,"phone":29,"phoneExt":20,"email":31},"Xavier ROMAND, MD, PHD",{"name":52,"role":28,"phone":53,"phoneExt":20,"email":34},"Emeric GREMEN, MD, PHD","0476765829",{"name":50,"role":25,"phone":20,"phoneExt":20,"email":20},{"type":56,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100563041",false,"NCT06611007","Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment","Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment: a Pilot Study of 15 Patients","EMBARDI","Inclusion Criteria:\n\n* Patients aged ≥ 40 years.\n* Osteoarthritis of the hand according to American College of Rheumatology criteria 1990\n* Osteoarthritis affecting at least two proximal and\u002For distal interphalangeal joints with a radiological Kellgren-Lawrence stage ≥ 2.\n* Symptomatic osteoarthritis within the last 3 months.\n* Visual analogue pain scale of the hand to be treated ≥ 40\u002F100 mm (most painful hand).\n* Inadequate response, adverse effects and\u002For contraindication to NSAIDs and non-opioid analgesics.\n* Patient affiliated to french social security or a similar health assurance.\n\nExclusion Criteria:\n\n* History of allergy to iodinated contrast media, LipiodolⓇ or poppies.\n* Vasomotor disorders (Raynaud\\'s syndrome, scleroderma, acrocyanosis).\n* Stenosis (\\>50%) or known atheromatous arterial occlusion of the upper limbs.\n* Obliterative arterial disease of the lower limbs at the critical ischaemia stage.\n* Severe to end-stage chronic renal insufficiency (glomerular filtration rate \\< 30ml\u002Fmin\u002F1.73m2), dialysis or renal transplant.\n* Arteritis such as thromboangiitis obliterans disease or other diseases\n* Previous thrombosis\u002Fdissection of the radial artery.\n* Chronic inflammatory rheumatic disease (rheumatoid arthritis, psoriatic arthritis, microcrystalline arthritis, etc.).\n* Known hyperthyroidism or large multinodular goiter.\n* Traumatic lesions, haemorrhages or chronic bleeding in the hand (not completely resolved within 3 months of the start of the lesion) requiring embolisation.\n* Pregnant or breast-feeding.\n* Patients covered by articles L1121-5 to L1121-8 of the French Public Health Code and\u002For who do not speak French.\n* Patients in a period of exclusion or in the course of another interventional clinical trial.","ALL","40 Years",{"count":67,"type":68},15,"ESTIMATED","INTERVENTIONAL",[71,72],"PHASE1","PHASE2","The goal of this clinical trial is to evaluate the safety of arterial embolization using Lipiodol® in patients with symptomatic hand osteoarthritis refractory to conventional treatment. It will also learn about the efficacy of arterial embolization with Lipiodol® in reducing pain and improving hand function.\n\nThe main questions it aims to answer are:\n\n* What are the side effects and complications associated with the Lipiodol® arterial embolization procedure?\n* Does arterial embolization reduce pain intensity and improve hand function?\n\nResearchers will evaluate patients over a 6-month period to assess the safety of Lipiodol® embolization and its impact on joint pain, swelling, and functional capacity. Participants will:\n\n* Undergo arterial embolization with Lipiodol®\n* Participate in regular follow-ups to monitor pain relief, hand function, and any side effects\n* Have imaging studies to assess changes in joint vascularisation and damage",[75],"Osteoarthritis",[77,78,79],"Therapeutic embolization","Safety","Hand osteoarthritis","2026-05-04",{"date":82,"type":83},"2026-05-05","ACTUAL",{"date":85,"type":83},"2025-01-30",{"date":87,"type":68},"2028-07-15",{"name":5,"class":6},1]